Go Pro
NASDAQ:HSIC

Henry Schein (HSIC) Stock Price, News & Analysis

Henry Schein logo
$85.75 +0.58 (+0.68%)
Closing price 04:00 PM Eastern
Extended Trading
$85.75 0.00 (0.00%)
As of 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Henry Schein Stock (NASDAQ:HSIC)

Advanced

Key Stats

Today's Range
$84.38
$86.32
50-Day Range
$73.90
$88.26
52-Week Range
$61.94
$89.34
Volume
1.22 million shs
Average Volume
1.39 million shs
Market Capitalization
$9.77 billion
P/E Ratio
25.91
Dividend Yield
N/A
Price Target
$89.36
Consensus Rating
Hold

Company Overview

Henry Schein, Inc. is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes. This includes practice management software, e-commerce platforms, digital imaging systems, and advanced sterilization and infection control solutions. The company also offers financial services, consulting, and supply chain management programs designed to help healthcare practices optimize inventory, reduce operating costs and comply with regulatory requirements.

Founded in 1932 by Henry Schein in Queens, New York, the company has grown from a small health products supplier into a Fortune 500 organization headquartered in Melville, New York. Over the decades, Henry Schein has expanded through strategic acquisitions and organic growth, establishing a presence in more than 30 countries and serving over one million customers worldwide. Its global logistics network and local market expertise enable rapid delivery of products and responsive support for healthcare professionals across North America, Europe, Asia Pacific, Latin America and Africa.

Under the leadership of Chairman and Chief Executive Officer Stanley M. Bergman, who joined the company in the late 1980s, Henry Schein has pursued a strategy centered on customer service excellence, innovation and partnerships. The company collaborates with manufacturers, technology developers and professional associations to introduce new solutions and best practices to the marketplace. With a commitment to sustainability and community engagement, Henry Schein continues to invest in research, education and outreach programs that support the health and well-being of practitioners and patients around the world.

AI Generated. May Contain Errors.

Henry Schein Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
69th Percentile Overall Score

HSIC MarketRank™: 

Henry Schein scored higher than 69% of companies evaluated by MarketBeat, and ranked 178th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Henry Schein has received a consensus rating of Hold. The company's average rating score is 2.47, and is based on no strong buy ratings, 8 buy ratings, 6 hold ratings, and 1 sell rating.

  • Upside/Downside

    The consensus price target for Henry Schein is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Henry Schein has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Henry Schein's stock forecast and price target.
  • Earnings Growth

    Earnings for Henry Schein are expected to grow by 9.40% in the coming year, from $5.32 to $5.82 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Henry Schein is 25.96, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.97.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Henry Schein is 25.96, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 281.85.

  • Price to Earnings Growth Ratio

    Henry Schein has a PEG Ratio of 1.65. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Henry Schein has a P/B Ratio of 2.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Henry Schein's valuation and earnings.
  • Percentage of Shares Shorted

    5.79% of the float of Henry Schein has been sold short.
  • Short Interest Ratio / Days to Cover

    Henry Schein has a short interest ratio ("days to cover") of 5.01.
  • Change versus previous month

    Short interest in Henry Schein has recently decreased by 8.29%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Henry Schein does not currently pay a dividend.

  • Dividend Growth

    Henry Schein does not have a long track record of dividend growth.

  • News Sentiment

    Henry Schein has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 15 news articles for Henry Schein this week, compared to 7 articles on an average week.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $691,900.00 in company stock, which represents 0.0071% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Henry Schein insiders have bought more of their company's stock than they have sold. Specifically, they have bought $691,900.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    0.89% of the stock of Henry Schein is held by insiders.

  • Percentage Held by Institutions

    96.62% of the stock of Henry Schein is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Henry Schein's insider trading history.
Receive HSIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Henry Schein and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

HSIC Stock News Headlines

Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.tc pixel
Henry Schein Announces Leadership Transitions
Henry Schein (HSIC) Gets a Hold from UBS
See More Headlines

HSIC Stock Analysis - Frequently Asked Questions

Henry Schein's stock was trading at $75.58 on January 1st, 2026. Since then, HSIC stock has increased by 13.7% and is now trading at $85.9650.

Henry Schein, Inc. (NASDAQ:HSIC) released its earnings results on Tuesday, May, 5th. The company reported $1.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.20 by $0.12. The business's revenue was up 6.3% on a year-over-year basis.
Read the conference call transcript
.

Shares of Henry Schein split on Friday, September 15th 2017.The 2-1 split was announced on Wednesday, August 16th 2017. The newly issued shares were issued to shareholders after the market closes on Thursday, September 14th 2017. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Henry Schein subsidiaries include Prism Medical Products LLC, Elite Computer Italia, Southern Anesthesia & Surgical, Marrodent, Dental Cremer, RxWorks, Dental Trey, and more.

Top institutional investors of Henry Schein include GHP Investment Advisors Inc. (0.05%), Assenagon Asset Management S.A. (0.04%), Czech National Bank (0.02%) and Mirae Asset Global Investments Co. Ltd. (0.02%). Insiders that own company stock include Stanley M Bergman, James P Breslawski, Michael S Ettinger, Thomas C Popeck, Mark E Mlotek, Lorelei Mcglynn, Bradford C Connett, Philip A Laskawy and Kurt P Kuehn.
View institutional ownership trends
.

Shares of HSIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Henry Schein investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR), AUO (AUOTY) and The RMR Group (RMR).

Company Calendar

Last Earnings
5/05/2026
Today
7/31/2026
Next Earnings (Estimated)
8/04/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Providers & Services
Sub-Industry
Healthcare Distributors
Current Symbol
NASDAQ:HSIC
CIK
1000228
Employees
25,000
Year Founded
1932

Price Target and Rating

High Price Target
$100.00
Low Price Target
$64.00
Potential Upside/Downside
+4.2%
Consensus Rating
Hold
Rating Score (0-4)
2.47
Research Coverage
15 Analysts

Profitability

EPS (Trailing Twelve Months)
$3.31
Trailing P/E Ratio
25.91
Forward P/E Ratio
16.12
P/E Growth
1.65
Net Income
$398 million
Net Margins
2.95%
Pretax Margin
4.02%
Return on Equity
15.44%
Return on Assets
5.53%

Debt

Debt-to-Equity Ratio
0.59
Current Ratio
1.36
Quick Ratio
0.75

Sales & Book Value

Annual Sales
$13.18 billion
Price / Sales
0.74
Cash Flow
$7.77 per share
Price / Cash Flow
11.03
Book Value
$33.12 per share
Price / Book
2.59

Miscellaneous

Outstanding Shares
113,920,000
Free Float
112,903,000
Market Cap
$9.77 billion
Optionable
Optionable
Beta
0.81

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:HSIC) was last updated on 7/31/2026 by MarketBeat.com Staff.
From Our Partners